<DOC>
	<DOCNO>NCT02353715</DOCNO>
	<brief_summary>This pilot exercise physiology quality life study subject receive standard care therapy prostate cancer use FDA-approved drug per labeling ( abiraterone , enzalutamide , sipuleucel-T ) . Subjects progressive , asymptomatic minimally symptomatic mCRPC schedule treat either enzalutamide abiraterone acetate ≥3 month course sipuleucel-T allocate one treatment arm , accord treatment chosen treat physician .</brief_summary>
	<brief_title>Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T ( Provenge® ) , Abiraterone Acetate ( Zytiga® ) Enzalutamide ( Xtandi® ) Undergoing Cardiopulmonary EXercise Testing</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Male age ≥ 18 year 2 . Histologicallyconfirmed adenocarcinoma prostate 3 . Surgically medically castrated 4 . Starting either enzalutamide abiraterone least 12 week OR start course sipuleucelT . Subjects treat concomitantly abiraterone enzalutamide plus sipuleucelT eligible enrol Arm A Arm B , appropriate . 5 . ECOG performance status 0 1 6 . Able read understand English , opinion treat provider , well enough complete study questionnaires 7 . Able comply study requirement 8 . Successful completion CPET opinion investigator 1 . Subjects surgical procedure ( i.e . TURP , etc . ) within 4 week prior enter study . 2 . Subjects receive treatment BOTH abiraterone enzalutamide 3 . For Arm C ( sipuleucelT ) : 1. subject receive abiraterone enzalutamide concomitantly sipuleucelT enrolled Arm A Arm B , appropriate . 2. subject receive prior sipuleucelT 4 . Subjects receive investigational agent ( i.e . enzalutamide abiraterone plus investigational drug ) . 5 . Subjects follow absolute contraindication maximal exercise test recommend American Thoracic Society exercise test guideline cancer subject , opinion treat provider : ( ) acute myocardial infarction ( 35 day ) , ( b ) unstable angina , ( c ) uncontrolled arrhythmias causing symptom hemodynamic compromise , ( ) syncope , ( e ) acute endocarditis , ( f ) acute myocarditis pericarditis , ( g ) uncontrolled heart failure , ( h ) acute pulmonary embolus pulmonary infarction , ( ) thrombosis low extremity , ( j ) suspect dissect aneurysm , ( k ) uncontrolled asthma , ( l ) pulmonary edema , ( ) room air desaturation rest &lt; 85 % , ( n ) respiratory failure , ( ) acute noncardiopulmonary disorder may affect exercise performance aggravate exercise , ( p ) mental impairment lead inability cooperate , ( q ) extensive bone metastasis . 6 . Significant cardiovascular disease , include : 1 . Symptomatic leave ventricular dysfunction know baseline leave ventricular ejection fraction ( LVEF ) multigated acquisition scan ( MUGA ) echocardiogram ( ECHO ) &lt; low limit institutional normal ( LLN ) . `` Symptomatic '' define New York Heart Association ( NYHA ) Class II great . Note : MUGA ECHCO NOT need measure establish eligibility study . 2 . Uncontrolled hypertension 3 . Myocardial infarction , severe angina , unstable angina within 6 month prior administration first dose study drug 4 . History serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ) within 12 month first dose study drug 5 . Uncontrolled cardiac arrhythmia 6 . Coronary peripheral artery bypass graft within 6 month first dose study drug 7 . History CVA , TIA , rest claudication within 6 month first dose study drug 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 8 . Known suspected brain metastasis leptomeningeal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>